Aspirin Dosing in Pregnancy

Aspirin Dosing and Platelet Phenotype in Pregnancy

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Inclusion Criteria:

• Pregnant people prior to 17 weeks
• Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
• Age 18-50 years
• Singleton viable gestation
• Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

Exclusion Criteria:

• Undergoing glucose challenge test (GCT) at time of blood draw
• Allergy or intolerance to aspirin
• Antithrombotic or antiplatelet therapy
• Anemia (hemoglobin <10 g/dl) or thrombocytopenia (platelet count <100,000), or thrombocytosis (platelet count >600,000)
• Known hemorrhagic diathesis
• Planned delivery outside of NYU